Refine search

Date
Tumour Site
Topics
Congress

146 results for ""

Suresh Ramalingam

How long should we give immunotherapy for?

The length of immunotherapy course for metastatic lung cancer was arbitrarily set at 2 years in clinical trials, but definitive studies investigating the optimum duration against the risk-benefit profile are lacking

By Suresh Ramalingam
Congress_audience_01

Is there a future for immunotherapy in sarcoma?

Continued efforts in patient selection, combination strategies and novel approaches may help to turn the tide for immunotherapeutics in sarcoma, according to Prof. Jean-Yves Blay 

Andrew J.S. Furness

Biomarkers for immunotherapy: where are we?

The future is in the hands of tools built on combinations of biomarkers as no single biomarker is likely to reflect the complexity of the tumour microenvironment or account for tumour evolution

By Andrew J.S. Furness

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.